UK markets open in 4 hours 33 minutes

Rigel Pharmaceuticals Inc (RI2A.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
0.8920+0.0585 (+7.02%)
At close: 09:36PM CEST
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
120,346
116,882
120,242
149,236
108,621
Cost of revenue
8,158
7,110
1,749
1,083
895
Gross profit
112,188
109,772
118,493
148,153
107,726
Operating expenses
Research development
20,459
24,522
60,272
65,237
60,101
Selling general and administrative
106,461
105,741
112,451
91,891
76,598
Total operating expenses
126,920
130,263
172,723
157,128
136,699
Operating income or loss
-14,732
-20,491
-54,230
-8,975
-28,973
Interest expense
7,542
6,872
3,707
4,860
1,353
Total other income/expenses net
-
-
-1,320
-3,521
-
Income before tax
-19,802
-25,091
-58,573
-17,309
-29,744
Income tax expense
-
0
0
605
0
Income from continuing operations
-19,802
-25,091
-58,573
-17,914
-29,744
Net income
-19,802
-25,091
-58,573
-17,914
-29,744
Net income available to common shareholders
-19,802
-25,091
-58,573
-17,914
-29,744
Basic EPS
-0.34
-0.14
-0.34
-0.11
-0.18
Diluted EPS
-0.34
-0.14
-0.34
-0.11
-0.18
Basic average shares
172,406
174,017
172,406
170,492
168,754
Diluted average shares
172,406
174,017
172,406
170,492
168,754